

Philip E Castle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5462751/publications.pdf>

Version: 2024-02-01

213
papers

13,995
citations

26567

56
h-index

22764

112
g-index

214
all docs

214
docs citations

214
times ranked

9175
citing authors

#	ARTICLE	IF	CITATIONS
1	Human papillomavirus and cervical cancer. <i>Lancet</i> , The, 2007, 370, 890-907.	6.3	2,343
2	2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. <i>Journal of Lower Genital Tract Disease</i> , 2020, 24, 102-131.	0.9	608
3	Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. <i>International Journal of Cancer</i> , 2009, 124, 516-520.	2.3	557
4	Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. <i>Lancet Oncology</i> , The, 2011, 12, 663-672.	5.1	504
5	Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. <i>Lancet Oncology</i> , The, 2011, 12, 880-890.	5.1	440
6	Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. <i>BMJ: British Medical Journal</i> , 2018, 363, k4823.	2.4	437
7	A Prospective Study of Age Trends in Cervical Human Papillomavirus Acquisition and Persistence in Guanacaste, Costa Rica. <i>Journal of Infectious Diseases</i> , 2005, 191, 1808-1816.	1.9	354
8	Epidemiologic Profile of Type-Specific Human Papillomavirus Infection and Cervical Neoplasia in Guanacaste, Costa Rica. <i>Journal of Infectious Diseases</i> , 2005, 191, 1796-1807.	1.9	322
9	Evidence for Frequent Regression of Cervical Intraepithelial Neoplasia Grade 2. <i>Obstetrics and Gynecology</i> , 2009, 113, 18-25.	1.2	321
10	Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study. <i>Lancet Oncology</i> , The, 2019, 20, 394-407.	5.1	279
11	Human Papillomavirus Type 16 Infections and 2-Year Absolute Risk of Cervical Precancer in Women With Equivocal or Mild Cytologic Abnormalities. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1066-1071.	3.0	273
12	HPV16 E7 Genetic Conservation Is Critical to Carcinogenesis. <i>Cell</i> , 2017, 170, 1164-1174.e6.	13.5	221
13	A Prospective Study of High-Grade Cervical Neoplasia Risk Among Human Papillomavirus-Infected Women. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1406-1414.	3.0	208
14	Reassurance Against Future Risk of Precancer and Cancer Conferred by a Negative Human Papillomavirus Test. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju153-dju153.	3.0	200
15	The Relationship of Community Biopsy-Diagnosed Cervical Intraepithelial Neoplasia Grade 2 to the Quality Control Pathology-Reviewed Diagnoses. <i>American Journal of Clinical Pathology</i> , 2007, 127, 805-815.	0.4	186
16	Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. <i>BMJ: British Medical Journal</i> , 2009, 339, b2569-b2569.	2.4	167
17	Comparisons of HPV DNA detection by MY09/11 PCR methods. <i>Journal of Medical Virology</i> , 2002, 68, 417-423.	2.5	158
18	Human Papillomavirus Genotype Specificity of Hybrid Capture 2. <i>Journal of Clinical Microbiology</i> , 2008, 46, 2595-2604.	1.8	156

#	ARTICLE	IF	CITATIONS
19	Anal Cancer Risk Among People With HIV Infection in the United States. <i>Journal of Clinical Oncology</i> , 2018, 36, 68-75.	0.8	152
20	Cervicovaginal microbiome and natural history of HPV in a longitudinal study. <i>PLoS Pathogens</i> , 2020, 16, e1008376.	2.1	150
21	HPV16 Sublineage Associations With Histology-Specific Cancer Risk Using HPV Whole-Genome Sequences in 3200 Women. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw100.	3.0	147
22	Chapter 4: Genital Tract Infections, Cervical Inflammation, and Antioxidant Nutrients—Assessing Their Roles as Human Papillomavirus Cofactors. <i>Journal of the National Cancer Institute Monographs</i> , 2003, 29-34.	0.9	144
23	Risk assessment to guide the prevention of cervical cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 197, 356.e1-356.e6.	0.7	140
24	p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive Women. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv257.	3.0	130
25	Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline. <i>Journal of Global Oncology</i> , 2017, 3, 635-657.	0.5	121
26	Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening. <i>Journal of the National Cancer Institute</i> , 2018, 110, 501-508.	3.0	116
27	Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines. <i>Journal of Lower Genital Tract Disease</i> , 2020, 24, 132-143.	0.9	116
28	A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs. <i>EClinicalMedicine</i> , 2020, 22, 100293.	3.2	109
29	Offering Self-Sampling Kits for HPV Testing to Reach Women Who Do Not Attend in the Regular Cervical Cancer Screening Program. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 769-772.	1.1	100
30	Clinical Evaluation of Human Papillomavirus Screening With p16/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening Program. <i>JAMA Internal Medicine</i> , 2019, 179, 881.	2.6	98
31	Five-Year Experience of Human Papillomavirus DNA and Papanicolaou Test Cotesting. <i>Obstetrics and Gynecology</i> , 2009, 113, 595-600.	1.2	97
32	A Cross-sectional Study of a Prototype Carcinogenic Human Papillomavirus E6/E7 Messenger RNA Assay for Detection of Cervical Precancer and Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 2599-2605.	3.2	95
33	Comparison of Linear Array and Line Blot Assay for Detection of Human Papillomavirus and Diagnosis of Cervical Precancer and Cancer in the Atypical Squamous Cell of Undetermined Significance and Low-Grade Squamous Intraepithelial Lesion Triage Study. <i>Journal of Clinical Microbiology</i> , 2008, 46, 109-117.	1.8	91
34	How to evaluate emerging technologies in cervical cancer screening?. <i>International Journal of Cancer</i> , 2009, 125, 2489-2496.	2.3	91
35	Population-Based Incidence Rates of Cervical Intraepithelial Neoplasia in the Human Papillomavirus Vaccine Era. <i>JAMA Oncology</i> , 2017, 3, 833.	3.4	88
36	Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA-positive, cytologically negative women. <i>Cancer</i> , 2002, 95, 2145-2151.	2.0	84

#	ARTICLE	IF	CITATIONS
37	Comparative community outreach to increase cervical cancer screening in the Mississippi Delta. <i>Preventive Medicine</i> , 2011, 52, 452-455.	1.6	82
38	Accuracy and Efficiency of Deep-Learning-Based Automation of Dual Stain Cytology in Cervical Cancer Screening. <i>Journal of the National Cancer Institute</i> , 2021, 113, 72-79.	3.0	82
39	A systematic review and meta-analysis on the attribution of human papillomavirus (HPV) in neuroendocrine cancers of the cervix. <i>Gynecologic Oncology</i> , 2018, 148, 422-429.	0.6	81
40	Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women. <i>JAMA Oncology</i> , 2019, 5, 181.	3.4	79
41	Comparison of Two PCR-Based Human Papillomavirus Genotyping Methods. <i>Journal of Clinical Microbiology</i> , 2008, 46, 3437-3445.	1.8	75
42	Human Papillomavirus DNA Methylation as a Biomarker for Cervical Precancer: Consistency across 12 Genotypes and Potential Impact on Management of HPV-Positive Women. <i>Clinical Cancer Research</i> , 2018, 24, 2194-2202.	3.2	75
43	A Comparison of Cervical and Vaginal Human Papillomavirus. <i>Sexually Transmitted Diseases</i> , 2007, 34, 849-855.	0.8	73
44	Relationship of Atypical Glandular Cell Cytology, Age, and Human Papillomavirus Detection to Cervical and Endometrial Cancer Risks. <i>Obstetrics and Gynecology</i> , 2010, 115, 243-248.	1.2	73
45	A Population-Based Study of Vaginal Human Papillomavirus Infection in Hysterectomized Women. <i>Journal of Infectious Diseases</i> , 2004, 190, 458-467.	1.9	72
46	The Age-Specific Relationships of Abnormal Cytology and Human Papillomavirus DNA Results to the Risk of Cervical Precancer and Cancer. <i>Obstetrics and Gynecology</i> , 2010, 116, 76-84.	1.2	71
47	Results of Human Papillomavirus DNA Testing with the Hybrid Capture 2 Assay Are Reproducible. <i>Journal of Clinical Microbiology</i> , 2002, 40, 1088-1090.	1.8	70
48	Cervical cancer prevention and control in women living with human immunodeficiency virus. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 505-526.	157.7	70
49	A cohort study of cervical screening using partial HPV typing and cytology triage. <i>International Journal of Cancer</i> , 2016, 139, 2606-2615.	2.3	68
50	Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial. <i>PLoS Medicine</i> , 2017, 14, e1002388.	3.9	67
51	Human Papillomavirus (HPV) Genotypes in Women with Cervical Precancer and Cancer at Kaiser Permanente Northern California. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 946-953.	1.1	66
52	Epidemiologic Evidence That Excess Body Weight Increases Risk of Cervical Cancer by Decreased Detection of Precancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1184-1191.	0.8	65
53	Risk of Cervical Precancer and Cancer Among HIV-Infected Women With Normal Cervical Cytology and No Evidence of Oncogenic HPV Infection. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 362-9.	3.8	63
54	Timely follow-up of positive cancer screening results: A systematic review and recommendations from the PROSPR Consortium. <i>Ca-A Cancer Journal for Clinicians</i> , 2018, 68, 199-216.	157.7	63

#	ARTICLE	IF	CITATIONS
55	Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries. <i>International Journal of Cancer</i> , 2016, 139, 2771-2780.	2.3	62
56	Risk Assessment to Guide the Prevention of Cervical Cancer. <i>Journal of Lower Genital Tract Disease</i> , 2008, 12, 1-7.	0.9	59
57	Interlaboratory reliability of Hybrid Capture 2. <i>American Journal of Clinical Pathology</i> , 2004, 122, 238-45.	0.4	59
58	Age of Acquiring Causal Human Papillomavirus (HPV) Infections: Leveraging Simulation Models to Explore the Natural History of HPV-induced Cervical Cancer. <i>Clinical Infectious Diseases</i> , 2017, 65, 893-899.	2.9	58
59	Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2002, 11, 1394-9.	1.1	57
60	Comparison between Prototype Hybrid Capture 3 and Hybrid Capture 2 Human Papillomavirus DNA Assays for Detection of High-Grade Cervical Intraepithelial Neoplasia and Cancer. <i>Journal of Clinical Microbiology</i> , 2003, 41, 4022-4030.	1.8	55
61	Treatment of cervical intraepithelial lesions. <i>International Journal of Gynecology and Obstetrics</i> , 2017, 138, 20-25.	1.0	53
62	Mutations in the HPV16 genome induced by APOBEC3 are associated with viral clearance. <i>Nature Communications</i> , 2020, 11, 886.	5.8	52
63	Evaluation of a Prototype Real-Time PCR Assay for Carcinogenic Human Papillomavirus (HPV) Detection and Simultaneous HPV Genotype 16 (HPV16) and HPV18 Genotyping. <i>Journal of Clinical Microbiology</i> , 2009, 47, 3344-3347.	1.8	50
64	Immunohistochemical evaluation of heat shock proteins in normal and preinvasive lesions of the cervix. <i>Cancer Letters</i> , 2005, 229, 245-252.	3.2	49
65	A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results. <i>Gynecologic Oncology</i> , 2015, 138, 573-578.	0.6	49
66	A Study of Partial Human Papillomavirus Genotyping in Support of the 2019 ASCCP Risk-Based Management Consensus Guidelines. <i>Journal of Lower Genital Tract Disease</i> , 2020, 24, 144-147.	0.9	48
67	Long-Term Persistence of Prevalently Detected Human Papillomavirus Infections in the Absence of Detectable Cervical Precancer and Cancer. <i>Journal of Infectious Diseases</i> , 2011, 203, 814-822.	1.9	47
68	Why does cervical cancer occur in a state-of-the-art screening program?. <i>Gynecologic Oncology</i> , 2017, 146, 546-553.	0.6	47
69	An Analysis of High-Risk Human Papillomavirus DNA-Negative Cervical Precancers in the ASCUS-LSIL Triage Study (ALTS). <i>Obstetrics and Gynecology</i> , 2008, 111, 847-856.	1.2	44
70	The Role of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Large-Scale Evaluation of the cobas HPV Test. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1304-1310.	1.1	44
71	Association of <scp>HPV35</scp> with cervical carcinogenesis among women of African ancestry: Evidence of viral-host interaction with implications for disease intervention. <i>International Journal of Cancer</i> , 2020, 147, 2677-2686.	2.3	44
72	Human Papillomavirus Genotypes in Cervical Intraepithelial Neoplasia Grade 3. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1675-1681.	1.1	43

#	ARTICLE	IF	CITATIONS
73	Real-world data on cervical cancer risk stratification by cytology and HPV genotype to inform the management of HPV-positive women in routine cervical screening. <i>British Journal of Cancer</i> , 2020, 122, 1715-1723.	2.9	43
74	Cervical concentrations of interleukin-10 and interleukin-12 do not correlate with plasma levels. <i>Journal of Clinical Immunology</i> , 2002, 22, 23-27.	2.0	42
75	Hormonal contraceptive use, pregnancy and parity, and the risk of cervical intraepithelial neoplasia 3 among oncogenic HPV DNA-positive women with equivocal or mildly abnormal cytology. <i>International Journal of Cancer</i> , 2005, 117, 1007-1012.	2.3	40
76	Comparison of Human Papillomavirus Detection by Aptima HPV and cobas HPV Tests in a Population of Women Referred for Colposcopy following Detection of Atypical Squamous Cells of Undetermined Significance by Pap Cytology. <i>Journal of Clinical Microbiology</i> , 2015, 53, 1277-1281.	1.8	39
77	Age-Specific Occurrence of HPV16- and HPV18-Related Cervical Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1313-1318.	1.1	38
78	Time for a Model List of Essential Diagnostics. <i>New England Journal of Medicine</i> , 2016, 374, 2511-2514.	13.9	36
79	Pilot Study of a Commercialized Human Papillomavirus (HPV) Genotyping Assay: Comparison of HPV Risk Group to Cytology and Histology. <i>Journal of Clinical Microbiology</i> , 2006, 44, 3915-3917.	1.8	35
80	The Clinical Meaning of a Cervical Intraepithelial Neoplasia Grade 1 Biopsy. <i>Obstetrics and Gynecology</i> , 2011, 118, 1222-1229.	1.2	35
81	A scoping review: Facilitators and barriers of cervical cancer screening and early diagnosis of breast cancer in Sub-Saharan African health settings. <i>Gynecologic Oncology Reports</i> , 2020, 33, 100605.	0.3	35
82	Sexual Behavior, Human Papillomavirus Type 16 (HPV 16) Infection, and HPV 16 Seropositivity. <i>Sexually Transmitted Diseases</i> , 2002, 29, 182-187.	0.8	34
83	<i>Chlamydia trachomatis</i> , Herpes Simplex Virus 2, and Human T-Cell Lymphotropic Virus Type 1 Are Not Associated With Grade of Cervical Neoplasia in Jamaican Colposcopy Patients. <i>Sexually Transmitted Diseases</i> , 2003, 30, 575-580.	0.8	34
84	Cervical Precancer Risk in HIV-Infected Women Who Test Positive for Oncogenic Human Papillomavirus Despite a Normal Pap Test. <i>Clinical Infectious Diseases</i> , 2015, 61, 1573-1581.	2.9	34
85	FightHPV: Design and Evaluation of a Mobile Game to Raise Awareness About Human Papillomavirus and Nudge People to Take Action Against Cervical Cancer. <i>JMIR Serious Games</i> , 2019, 7, e8540.	1.7	34
86	Comparison of Ophthalmic Sponges for Measurements of Immune Markers from Cervical Secretions. <i>Vaccine Journal</i> , 2004, 11, 399-405.	3.2	33
87	The evolving definition of carcinogenic human papillomavirus. <i>Infectious Agents and Cancer</i> , 2009, 4, 7.	1.2	33
88	Smoking and subsequent human papillomavirus infection: a mediation analysis. <i>Annals of Epidemiology</i> , 2017, 27, 724-730.e1.	0.9	33
89	Beyond Human Papillomavirus: The Cervix, Exogenous Secondary Factors, and the Development of Cervical Precancer and Cancer. <i>Journal of Lower Genital Tract Disease</i> , 2004, 8, 224-230.	0.9	32
90	Safety and acceptability of human papillomavirus testing of self-collected specimens: A methodologic study of the impact of collection devices and HPV assays on sensitivity for cervical cancer and high-grade lesions. <i>Journal of Clinical Virology</i> , 2018, 99-100, 22-30.	1.6	32

#	ARTICLE	IF	CITATIONS
91	Hybrid capture 2 viral load and the 2-year cumulative risk of cervical intraepithelial neoplasia grade 3 or cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2004, 191, 1590-1597.	0.7	31
92	Meta-analysis of agreement/concordance statistics in studies comparing self-collected samples for HPV testing in cervical cancer screening. <i>International Journal of Cancer</i> , 2022, 151, 308-312.	2.3	31
93	Relationships of p16 Immunohistochemistry and Other Biomarkers With Diagnoses of Cervical Abnormalities: Implications for LAST Terminology. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 725-734.	1.2	30
94	5-Year Prospective Evaluation of Cytology, Human Papillomavirus Testing, and Biomarkers for Detection of Anal Precancer in Human Immunodeficiency Virus-Positive Men Who Have Sex With Men. <i>Clinical Infectious Diseases</i> , 2019, 69, 631-638.	2.9	29
95	Invited Commentary: Is Monitoring of Human Papillomavirus Infection for Viral Persistence Ready for Use in Cervical Cancer Screening?. <i>American Journal of Epidemiology</i> , 2008, 168, 138-144.	1.6	28
96	Age-appropriate use of human papillomavirus vaccines in the U.S.. <i>Gynecologic Oncology</i> , 2009, 114, 365-369.	0.6	28
97	Design and feasibility of a novel program of cervical screening in Nigeria: self-sampled HPV testing paired with visual triage. <i>Infectious Agents and Cancer</i> , 2020, 15, 60.	1.2	27
98	Impact of Improved Classification on the Association of Human Papillomavirus With Cervical Precancer. <i>American Journal of Epidemiology</i> , 2010, 171, 155-163.	1.6	26
99	Clinical Outcomes after Conservative Management of Cervical Intraepithelial Neoplasia Grade 2 (CIN2) in Women Ages 21-39 Years. <i>Cancer Prevention Research</i> , 2018, 11, 165-170.	0.7	26
100	Mixture models for undiagnosed prevalent disease and interval-censored incident disease: applications to a cohort assembled from electronic health records. <i>Statistics in Medicine</i> , 2017, 36, 3583-3595.	0.8	25
101	Health Service Accessibility and Risk in Cervical Cancer Prevention: Comparing Rural Versus Nonrural Residence in New Mexico. <i>Journal of Rural Health</i> , 2017, 33, 382-392.	1.6	25
102	Diagnosing Cervical Neoplasia in Rural Brazil Using a Mobile Van Equipped with <i>In Vivo</i> Microscopy: A Cluster-Randomized Community Trial. <i>Cancer Prevention Research</i> , 2018, 11, 359-370.	0.7	25
103	Human Papillomavirus Prevalence in Women Who Have and Have Not Undergone Hysterectomies. <i>Journal of Infectious Diseases</i> , 2006, 194, 1702-1705.	1.9	24
104	A Comparison of Human Papillomavirus Genotype-Specific DNA and E6/E7 mRNA Detection to Identify Anal Precancer among HIV-Infected Men Who Have Sex with Men. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 42-49.	1.1	23
105	Social contexts as mediator of risk behaviors in Rwandan men who have sex with men (MSM): Implications for HIV and STI transmission. <i>PLoS ONE</i> , 2019, 14, e0211099.	1.1	23
106	Secondary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline Summary. <i>Journal of Oncology Practice</i> , 2017, 13, 129-133.	2.5	22
107	A common clinical dilemma: Management of abnormal vaginal cytology and human papillomavirus test results. <i>Gynecologic Oncology</i> , 2016, 141, 364-370.	0.6	21
108	Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results. <i>Preventive Medicine</i> , 2019, 118, 44-50.	1.6	21

#	ARTICLE	IF	CITATIONS
109	Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia. <i>BMJ Open</i> , 2018, 8, e016700.	0.8	20
110	The cost-effectiveness of implementing HPV testing for cervical cancer screening in El Salvador. <i>International Journal of Gynecology and Obstetrics</i> , 2019, 145, 40-46.	1.0	20
111	Participation in Cervical Screening by Self-collection, Pap, or a Choice of Either in Brazil. <i>Cancer Prevention Research</i> , 2019, 12, 159-170.	0.7	20
112	Validation of a Human Papillomavirus (HPV) DNA Cervical Screening Test That Provides Expanded HPV Typing. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	1.8	18
113	High-risk human papillomavirus prevalence in self-collected cervicovaginal specimens from human immunodeficiency virus (HIV)-negative women and women living with HIV living in Botswana. <i>PLoS ONE</i> , 2020, 15, e0229086.	1.1	18
114	Factors Influencing Histologic Confirmation of High-Grade Squamous Intraepithelial Lesion Cytology. <i>Obstetrics and Gynecology</i> , 2008, 112, 637-645.	1.2	17
115	Prevalence and risk factors for High-Risk Human Papillomavirus (hrHPV) infection among HIV-infected and Uninfected Rwandan women: implications for hrHPV-based screening in Rwanda. <i>Infectious Agents and Cancer</i> , 2014, 9, 40.	1.2	17
116	Cervical cancer prevention in El Salvador (CAPE)-An HPV testing-based demonstration project: Changing the secondary prevention paradigm in a lower middle-income country. <i>Gynecologic Oncology Reports</i> , 2017, 20, 58-61.	0.3	17
117	A pilot study to compare dry cervical sample collection with standard practice of wet cervical samples for human papillomavirus testing. <i>Journal of Clinical Virology</i> , 2015, 69, 210-213.	1.6	16
118	Risk assessment to guide cervical screening strategies in a large Chinese population. <i>International Journal of Cancer</i> , 2016, 138, 2639-2647.	2.3	16
119	Challenges and opportunities associated with cervical cancer screening programs in a low income, high HIV prevalence context. <i>BMC Women's Health</i> , 2021, 21, 74.	0.8	16
120	National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study. <i>BMJ</i> , The, 2022, 376, e068582.	3.0	16
121	Neither one-time negative screening tests nor negative colposcopy provides absolute reassurance against cervical cancer. <i>International Journal of Cancer</i> , 2009, 125, 1649-1656.	2.3	15
122	Challenges in risk estimation using routinely collected clinical data: The example of estimating cervical cancer risks from electronic health-records. <i>Preventive Medicine</i> , 2018, 111, 429-435.	1.6	15
123	A study of the risks of CIN3+ detection after multiple rounds of HPV testing: Results of the 15-year cervical cancer screening experience at Kaiser Permanente Northern California. <i>International Journal of Cancer</i> , 2020, 147, 1612-1620.	2.3	15
124	A new method to address verification bias in studies of clinical screening tests: cervical cancer screening assays as an example. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 343-353.	2.4	14
125	Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 36-42.	1.1	14
126	Screening to Prevent Invasive Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2017, 35, 1250-1252.	0.8	14

#	ARTICLE	IF	CITATIONS
127	Adherence patterns to extended cervical screening intervals in women undergoing human papillomavirus (HPV) and cytology cotesting. <i>Preventive Medicine</i> , 2018, 109, 44-50.	1.6	14
128	Pathways to a cancer-free future: A protocol for modelled evaluations to maximize the future impact of interventions on cervical cancer in Australia. <i>Gynecologic Oncology</i> , 2019, 152, 465-471.	0.6	14
129	Mouthwash as a Low-Cost and Safe Specimen Transport Medium for Human Papillomavirus DNA Testing of Cervicovaginal Specimens. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 840-843.	1.1	13
130	The Potential Utility of HPV Genotyping in Screening and Clinical Management. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008, 6, 83-95.	2.3	13
131	Variable Risk of Cervical Precancer and Cancer After a Human Papillomavirus "Positive Test. <i>Obstetrics and Gynecology</i> , 2011, 117, 650-656.	1.2	13
132	The Cost-Effectiveness of Visual Triage of Human Papillomavirus "Positive Women in Three Low- and Middle-Income Countries. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1500-1510.	1.1	13
133	The burden of cervical cancer in Vietnam: Synthesis of the evidence. <i>Cancer Epidemiology</i> , 2019, 59, 83-103.	0.8	13
134	Effects of Electron-Beam Irradiation on Buccal-Cell DNA. <i>American Journal of Human Genetics</i> , 2003, 73, 646-651.	2.6	12
135	Cervical Precancer and Cancer Risk by Human Papillomavirus Status and Cytologic Interpretation: Implications for Risk-Based Management. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1595-1599.	1.1	12
136	Automated Cervical Screening and Triage, Based on HPV Testing and Computer-Interpreted Cytology. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1222-1228.	3.0	12
137	Protocol for the study of cervical cancer screening technologies in HIV-infected women living in Rwanda. <i>BMJ Open</i> , 2018, 8, e020432.	0.8	12
138	(At Least) Once in Her Lifetime: Global Cervical Cancer Prevention. <i>Obstetrics and Gynecology Clinics of North America</i> , 2019, 46, 107-123.	0.7	12
139	Perceived Susceptibility to Cervical Cancer among African American Women in the Mississippi Delta: Does Adherence to Screening Matter?. <i>Women's Health Issues</i> , 2019, 29, 38-47.	0.9	12
140	Outcomes for Step-Wise Implementation of a Human Papillomavirus Testing-Based Cervical Screen-and-Treat Program in El Salvador. <i>JCO Global Oncology</i> , 2020, 6, 1519-1530.	0.8	12
141	The Capulana study: a prospective evaluation of cervical cancer screening using human papillomavirus testing in Mozambique. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1292-1297.	1.2	12
142	Cervical Precancers and Cancers Attributed to HPV Types by Race and Ethnicity: Implications for Vaccination, Screening, and Management. <i>Journal of the National Cancer Institute</i> , 2022, 114, 845-853.	3.0	12
143	HPV testing of self-samples: Influence of collection and sample handling procedures on clinical accuracy to detect cervical precancer. <i>Lancet Regional Health - Europe</i> , The, 2022, 14, 100332.	3.0	12
144	Detection of Carcinogenic Human Papillomavirus in Specimens Collected with a Novel Self-Sampling Device. <i>Journal of Clinical Microbiology</i> , 2006, 44, 2158-2159.	1.8	11

#	ARTICLE	IF	CITATIONS
145	PSA testing for prostate cancer screening. <i>Lancet Oncology</i> , The, 2015, 16, e2-e3.	5.1	11
146	A risk-based framework to decide who benefits from screening. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 531-532.	12.5	11
147	Given a choice between self-sampling at home for HPV testing and standard of care screening at the clinic, what do African American women choose? Findings from a group randomized controlled trial. <i>Preventive Medicine</i> , 2021, 142, 106358.	1.6	11
148	The reliability of high-risk human papillomavirus detection by Aptima HPV assay in women with ASC-US cytology. <i>Journal of Clinical Virology</i> , 2015, 69, 52-55.	1.6	10
149	A paper-based immunoassay to determine HPV vaccination status at the point-of-care. <i>Vaccine</i> , 2016, 34, 5656-5663.	1.7	10
150	Quality assurance of human papillomavirus (HPV) testing in the implementation of HPV primary screening in Norway: an inter-laboratory reproducibility study. <i>BMC Infectious Diseases</i> , 2016, 16, 698.	1.3	10
151	Assessment of a New Lower-Cost Real-Time PCR Assay for Detection of High-Risk Human Papillomavirus: Useful for Cervical Screening in Limited-Resource Settings?. <i>Journal of Clinical Microbiology</i> , 2017, 55, 2348-2355.	1.8	10
152	Immune profiling of plasma and cervical secretions using recycling immunoaffinity chromatography. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2003, 12, 1449-56.	1.1	10
153	Three-Year Risk of Cervical Precancer and Cancer After the Detection of Low-Risk Human Papillomavirus Genotypes Targeted by a Commercial Test. <i>Obstetrics and Gynecology</i> , 2014, 123, 49-56.	1.2	9
154	Can a gastric cancer risk survey identify high-risk patients for endoscopic screening? A pilot study. <i>Journal of Surgical Research</i> , 2018, 227, 246-256.	0.8	9
155	Epidemiological evidence that common HPV types may be common because of their ability to evade immune surveillance: Results from the Women's Interagency HIV study. <i>International Journal of Cancer</i> , 2020, 146, 3320-3328.	2.3	9
156	The cost-effectiveness of human papillomavirus self-collection among cervical cancer screening non-attenders in El Salvador. <i>Preventive Medicine</i> , 2020, 131, 105931.	1.6	9
157	A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States. <i>Gynecologic Oncology</i> , 2020, 159, 344-353.	0.6	9
158	Anogenital Human Papillomavirus and HIV Infection in Rwandan Men Who Have Sex With Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 463-469.	0.9	9
159	Cervical cancer prevention in El Salvador: A prospective evaluation of screening and triage strategies incorporating high-resolution microendoscopy to detect cervical precancer. <i>International Journal of Cancer</i> , 2021, 148, 2571-2578.	2.3	9
160	Feasibility and performance of the fecal immunochemical test (FIT) for average-risk colorectal cancer screening in Nigeria. <i>PLoS ONE</i> , 2021, 16, e0243587.	1.1	9
161	Genetic and Epigenetic Variations of HPV52 in Cervical Precancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6463.	1.8	9
162	Twelve-Year Trend in the Prevalence of High-Risk Human Papillomavirus Infection Among Rwandan Women Living With HIV. <i>Journal of Infectious Diseases</i> , 2020, 222, 74-81.	1.9	9

#	ARTICLE	IF	CITATIONS
163	Influence of Loop Electrosurgical Excision Procedure on Subsequent Acquisition of New Human Papillomavirus Infections. <i>Journal of Infectious Diseases</i> , 2009, 199, 1612-1620.	1.9	8
164	Primary HPV and Molecular Cervical Cancer Screening in US Women Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 72, 1529-1537.	2.9	8
165	A lay health worker intervention to improve breast and cervical cancer screening among Latinas in El Paso, Texas: A randomized control trial. <i>Preventive Medicine</i> , 2021, 145, 106446.	1.6	8
166	Cervical human papillomavirus DNA detection in women living with HIV and HIV-uninfected women living in Limbe, Cameroon. <i>Journal of Clinical Virology</i> , 2020, 128, 104445.	1.6	8
167	Association of High-Risk Human Papillomavirus with Genital Tract Mucosal Immune Factors in HIV-Infected Women. <i>American Journal of Reproductive Immunology</i> , 2016, 75, 146-154.	1.2	7
168	Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S.. <i>Preventive Medicine</i> , 2018, 111, 177-179.	1.6	7
169	Phylogenomic Analysis of Human Papillomavirus Type 31 and Cervical Carcinogenesis: A Study of 2093 Viral Genomes. <i>Viruses</i> , 2021, 13, 1948.	1.5	7
170	Impact of 6-month frozen storage of cervical specimens in alkaline buffer conditions on human papillomavirus genotyping. <i>Journal of Virological Methods</i> , 2008, 151, 298-300.	1.0	6
171	Effect of the Number of Biopsies on the Subsequent Acquisition of New Human Papillomavirus Infections. <i>Obstetrics and Gynecology</i> , 2009, 114, 1057-1062.	1.2	6
172	Safety Against Cervical Precancer and Cancer Following Negative Human Papillomavirus and Papanicolaou Test Results in Human Immunodeficiency Virus-Infected Women. <i>Archives of Internal Medicine</i> , 2012, 172, 1041-3.	4.3	6
173	Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. <i>Cancer Cytopathology</i> , 2015, 123, 566-566.	1.4	6
174	A joint model of persistent human papilloma virus infection and cervical cancer risk: implications for cervical cancer screening. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , 2015, 178, 903-923.	0.6	6
175	A Pooled Analysis to Compare the Clinical Characteristics of Human Papillomavirus-positive and -Negative Cervical Precancers. <i>Cancer Prevention Research</i> , 2020, 13, 829-840.	0.7	6
176	Automated Evaluation of p16/Ki-67 Dual-Stain Cytology as a Biomarker for Detection of Anal Precancer in Men Who Have Sex With Men and Are Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2022, 75, 1565-1572.	2.9	6
177	Low Risk of Cervical Cancer/Precancer Among Most Women Under Surveillance Postcolposcopy. <i>Journal of Lower Genital Tract Disease</i> , 2018, 22, 97-103.	0.9	5
178	Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting. <i>International Journal of Cancer</i> , 2020, 146, 617-626.	2.3	5
179	Utilizing Cultural and Ethnic Variables in Screening Models to Identify Individuals at High Risk for Gastric Cancer: A Pilot Study. <i>Cancer Prevention Research</i> , 2020, 13, 687-698.	0.7	5
180	Comparison of immediate colposcopy, repeat conventional cytology and high-risk human papillomavirus testing for the clinical management of atypical squamous cells of undetermined significance cytology in routine health services of Medellin, Colombia: The <sc>ASCUS-</sc>COL trial. <i>International Journal of Cancer</i> , 2021, 148, 1394-1407.	2.3	5

#	ARTICLE	IF	CITATIONS
181	Type-specific persistence, clearance and incidence of high-risk HPV among screen-positive Rwandan women living with HIV. <i>Infectious Agents and Cancer</i> , 2021, 16, 16.	1.2	5
182	Adherence to National Guidelines on Cervical Screening: A Population-Based Evaluation From a Statewide Registry. <i>Journal of the National Cancer Institute</i> , 2022, 114, 626-630.	3.0	5
183	Different human papillomavirus types share early natural history transitions in immunocompetent women. <i>International Journal of Cancer</i> , 2022, 151, 920-929.	2.3	5
184	Age of human papillomavirus vaccination?. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 1091-1093.	4.6	4
185	An Exploratory Analysis of Fecal Immunochemical Test Performance for Colorectal Cancer Screening in Nigeria. <i>World Journal of Surgery</i> , 2019, 43, 2674-2680.	0.8	4
186	A comparison of screening tests for detection of high-grade cervical abnormalities in women living with HIV from Cameroon. <i>Infectious Agents and Cancer</i> , 2020, 15, 45.	1.2	4
187	When Is It Effective to Offer Self-Sampling to Non-Attendees? Letter. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1295-1295.	1.1	3
188	Charting the Future of Cancer Health Disparities Research? Letter. <i>Cancer Research</i> , 2018, 78, 1883-1885.	0.4	3
189	A Pilot Study of Human Papillomavirus Detection in Urine Using a Novel Nucleic Acid Amplification Test. <i>Journal of Applied Laboratory Medicine</i> , The, 2021, 6, 474-479.	0.6	3
190	The relationship of human papillomavirus and cytology co-testing results with endometrial and ovarian cancer diagnoses. <i>Gynecologic Oncology</i> , 2021, 161, 297-303.	0.6	3
191	The Improving Risk Informed HPV Screening (IRIS) Study: Design and Baseline Characteristics. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, , cebp.0865.2021.	1.1	3
192	Redefining precision cancer prevention to promote health equity. <i>Trends in Cancer</i> , 2022, 8, 295-302.	3.8	3
193	Commentary on Statement on HPV DNA Test Utilization. <i>American Journal of Clinical Pathology</i> , 2009, 131, 770-773.	0.4	2
194	PCR testing of pooled longitudinally collected cervical specimens of women to increase the efficiency of studying human papillomavirus infection. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 256-60.	1.1	2
195	Cervical HPV DNA Detection as a Predictor of a Recurrent SIL Diagnosis Among Untreated Women. <i>Journal of Lower Genital Tract Disease</i> , 2001, 5, 138-143.	0.9	1
196	Cervical Cancers After Human Papillomavirus Vaccination. <i>Obstetrics and Gynecology</i> , 2009, 114, 174.	1.2	1
197	When Less is More. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw240.	3.0	1
198	Letter to the Editor Re: A population study of screening history and diagnostic outcomes of women with invasive cervical cancer. <i>Cancer Medicine</i> , 2021, 10, 7263-7264.	1.3	1

#	ARTICLE	IF	CITATIONS
199	Response. Journal of the National Cancer Institute, 2014, 107, dju390-dju390.	3.0	0
200	Response. Journal of the National Cancer Institute, 2016, 108, djv390.	3.0	0
201	Correspondence regarding Suba et al., human papillomavirus screening for low and middle-income countries. Preventive Medicine, 2017, 105, 356.	1.6	0
202	Reply to M. Swanson et al. Journal of Global Oncology, 2018, 4, 1-2.	0.5	0
203	Towards global elimination of cervical cancer in all groups of women – Authors' reply. Lancet Oncology, The, 2019, 20, e239.	5.1	0
204	Is It Time for Risk-based Screening Guidelines for the Prevention of Anal Cancer?. Clinical Infectious Diseases, 2020, 73, 30-32.	2.9	0
205	Reply to: Comments on Cervical cancer prevention in El Salvador: A prospective evaluation of screening and triage strategies incorporating high-resolution microendoscopy to detect cervical precancer. International Journal of Cancer, 2021, 149, 969-971.	2.3	0
206	Letter to the Editor: Persisting Health Disparities in Women Living with HIV from the US. Clinical Infectious Diseases, 2021, , .	2.9	0
207	A pilot case control study: Could a gastric cancer risk screening tool help identify high risk patients for endoscopic screening in the United States?. Journal of Clinical Oncology, 2018, 36, 64-64.	0.8	0
208	A novel filtration-based processing method of liquid cytology specimens for human papillomavirus DNA testing by hybrid capture II. American Journal of Clinical Pathology, 2005, 123, 250-5.	0.4	0
209	Reply to: Comments on ‘‘Meta-analysis of agreement/concordance statistics in studies comparing self-collected vs clinician-collected samples for HPV testing in cervical cancer screening’’. International Journal of Cancer, 2022, 151, 484-487.	2.3	0
210	Title is missing!. , 2020, 15, e0229086.		0
211	Title is missing!. , 2020, 15, e0229086.		0
212	Title is missing!. , 2020, 15, e0229086.		0
213	Title is missing!. , 2020, 15, e0229086.		0